|Assessment Status||Rapid Review Complete|
|Drug||Recombinant Human Parathyroid Hormone|
|Indication||Is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.|
|Rapid review commissioned||05/03/2018|
|Rapid review completed||21/05/2018|
|Rapid review outcome||A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of Natpar compared with the current standard of care.|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.